Volume 15, Issue 2 (March & April 2024)                   BCN 2024, 15(2): 165-174 | Back to browse issues page

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Atak E S, Yıldız D, Kocatürk R R, Temizyürek A, Özcan Ö Ö, Ergüzel T T, et al . Therapeutic Targets of Probiotics in Parkinson Disease: A Systematic Review of Randomized Controlled Trials. BCN 2024; 15 (2) :165-174
URL: http://bcn.iums.ac.ir/article-1-2262-en.html
1- Department of Nutrition and Dietetics, Faculty of Health Sciences, Üsküdar University, Istanbul, Turkey.
2- Department of Physiology, School of Medicine, Koç University, Istanbul, Turkey.
3- Department of Molecular Neuroscience, Health Sciences Institute, Üsküdar University, Istanbul, Turkey.
4- Department of Software Engineering, Faculty of Engineering and Natural Sciences, Üsküdar University, Istanbul, Turkey.
5- Department of Psychiatry, School of Medicine, Üskudar University, Istanbul, Turkey.
Introduction: Parkinson disease is the world’s second most prevalent neurological disease. In this disease, intracytoplasmic neuronal inclusions are observed in enteric neurons in the gastrointestinal tract, and the composition of the intestinal microbiome is altered. These changes correlate with the motor phenotype. A systematic review was conducted to determine the effect of using probiotics in Parkinson disease.
Methods: Scopus, PubMed, Web of Science, the Cochrane Library, ScienceDirect, and Ovıd-LWW were searched until April 2021. A total of 27395 records were found according to inclusion and exclusion criteria with the following outcomes: Parkinson disease rating, oxidative stress, and gastrointestinal system markers. Data search, article selection, and data extraction assessments were performed according to the PRISMA (preferred reporting items for systematic reviews and meta-analyses) guidelines. The Jadad scale was used to rate the evidence’s quality.
Results: Our study information was gathered from 5 randomized controlled trials involving 350 individuals with Parkinson disease receiving probiotic supplements. Parkinson disease rating and non-motor symptoms test were performed in the samples. Also, oxidative stress (glutathione, malondialdehyde) and gastrointestinal system symptoms (bowel opening frequency, gut transit time, complete bowel movement, spontaneous bowel movements) were evaluated during 4-12 weeks of using probiotics in these patients. 
Conclusion: While all high-quality studies demonstrate improvement in disease symptoms of the patients, currently sufficient data are not available to recommend the use of probiotics for people with Parkinson disease in clinical practice.
Full-Text [PDF 696 kb]   |   |   Full-Text (HTML)   
Type of Study: Review | Subject: Clinical Neuroscience
Received: 2021/03/7 | Accepted: 2021/10/26 | Published: 2024/03/1

Add your comments about this article : Your username or Email:

Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2024 CC BY-NC 4.0 | Basic and Clinical Neuroscience

Designed & Developed by : Yektaweb